{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:52:42Z","timestamp":1756385562530},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,6,28]],"date-time":"2004-06-28T00:00:00Z","timestamp":1088380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Alicia and Alberto Tattar Foundation"},{"name":"Banco de Drogas Antineopl\u00e1sicas (BADAN) Foundation"},{"name":"Ni\u00f1os con Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2004,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We analyzed the results of the LMB\u201089 protocol performed in seven centers in Venezuela in 96 children having B\u2010cell non\u2010Hodgkin lymphoma treated from 1995 to 2002.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Mean age was 7.1 years with 71 (74%) been male. Eighty\u2010two patients (85%) had diffuse small cell lymphoma Burkitt and Burkitt\u2010like, and 14 (15%) had diffuse large B\u2010cell lymphoma. Initial disease sites included the abdomen in 67%, peripheral nodes in 8%, and mediastinal in 4%. Treatment was directed to risk groups as described for LMB\u201089 protocol. Group A: seven patients (7%), group B: 80 patients (83%), and group C: nine patients (9%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean follow\u2010up was 35\u2009\u00b1\u200931 months. Complete remission (CR) occurred in 70 patients (73%); four patients (6%) had relapse during the first year and ten patients (10%) had progressive disease. Overall survival (OS) and event free survival (EFS) were 85 and 80% at 1 year, and 82 and 75% at 2 years, respectively. The EFS by therapeutic groups at 3 years was A: 100%; B: 76%, and C: 56%. Toxicity: neutropenia in 75%, thrombocytopenia in 63%, febrile neutropenia in 39%. Viral infections: hepatitis B in 20%, hepatitis C in 2%, and Herpes zoster in 3%. Tumor lysis syndrome (TLS) occurred in 9% during induction phase with a high mortality of 44% (urate\u2010oxidase was available only at the end of the study).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The high mortality rate during induction phase prohibited a better EFS. Prophylactic use of xantine\u2010oxidase may improve future results. The high incidence of hepatitis B requires a vaccination program. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20116","type":"journal-article","created":{"date-parts":[[2004,6,29]],"date-time":"2004-06-29T07:01:42Z","timestamp":1088492502000},"page":"580-586","source":"Crossref","is-referenced-by-count":22,"title":["Outcome of children with B cell lymphoma in Venezuela with the LMB\u201089 protocol"],"prefix":"10.1002","volume":"43","author":[{"given":"G.","family":"Acquatella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.L.","family":"Insausti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Nouel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,6,28]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"329","article-title":"Classification staging and end results of treatment of childhood non\u2010Hodgkin's lymphomas: Dissimilarities from lymphomas in adults","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Semin Oncol"},{"key":"e_1_2_6_3_2","first-page":"253","article-title":"Linfoma no\u2010Hodgkin en ni\u00f1os. Experiencia de 30 pacientes en el Hospital Universitario de Caracas","volume":"30","author":"Acquatella G","year":"1985","journal-title":"Sangre (Espa\u00f1a)"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7"},{"key":"e_1_2_6_5_2","first-page":"1355","article-title":"Linfoma no\u2010Hodgkin en ni\u00f1os, resultados con el esquema LSA2 L2 en 30 pacientes Unidad de Linfomas, Hospital Universitario de Caracas","volume":"37","author":"Acquatella G","year":"1991","journal-title":"Cancerolog\u00eda (M\u00e9xico)"},{"key":"e_1_2_6_6_2","first-page":"208","article-title":"Linfomas en ni\u00f1os. Revisi\u00f3n de la Literatura Nacional","volume":"3","author":"Insausti CL","year":"1995","journal-title":"Gac Med Caracas"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303103081003"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.123"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950200204"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_13_2","first-page":"49","article-title":"An\u00e1lisis de 32 ni\u00f1os con Leucosis Linfobl\u00e1stica Aguda","volume":"20","author":"Perera A","year":"1987","journal-title":"Acta Odontol Venez"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(99)00455-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019509029551"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(200007)35:1<47::AID-MPO8>3.0.CO;2-N"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605093341906"},{"key":"e_1_2_6_18_2","first-page":"25","article-title":"Linfoma no\u2010Hodgkin en ni\u00f1os. Experiencia de 25 a\u00f1os de tratamiento en Venezuela","volume":"12","author":"Insausti CL","year":"2002","journal-title":"Rev Chil Cancerol Hematol"},{"key":"e_1_2_6_19_2","first-page":"205","article-title":"Tumores pedi\u00e1tricos linfohematopoy\u00e9ticos malignos: Caracter\u00edsticas cl\u00ednicas y patol\u00f3gicas en 127 pacientes","volume":"25","author":"Lara CC","year":"1992","journal-title":"Patolog\u00eda (Espa\u00f1a)"},{"key":"e_1_2_6_20_2","first-page":"40","article-title":"An\u00e1lisis comparativo de 3 reg\u00edmenes de tratamiento en ni\u00f1os con linfoma de Burkitt","volume":"3","author":"C\u00e1rdenas Card\u00f3s R","year":"2001","journal-title":"Oncolog\u00eda (M\u00e9xico)"},{"key":"e_1_2_6_21_2","first-page":"64","article-title":"Tumores s\u00f3lidos en ni\u00f1os, experiencia del Hospital de Ni\u00f1os. J. M de los R\u00edos. Caracas, Venezuela","volume":"9","author":"Pereira A","year":"1997","journal-title":"Rev Venez Oncol"},{"key":"e_1_2_6_22_2","first-page":"247","article-title":"Biology and therapy of B\u2010cell lymphoma in children: Are there lessons applicable to adult B\u2010Cell lymphoma?","author":"Murphy SB","year":"2001","journal-title":"ASCO 2001 Educ Book"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.1995.13.8.2023","article-title":"B\u2010cell lineage confers a favorable outcome among children and adolescent with large\u2010cell lymphoma: Pediatric Oncology Group Study","volume":"13","author":"Hutchison RE","year":"1995","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90038-1"},{"issue":"1","key":"e_1_2_6_25_2","first-page":"38","article-title":"S\u00edndrome de Lisis Tumoral en Pacientes Pedi\u00e1tricos con Linfoma tipo Burkitt","volume":"15","author":"Santos S","year":"2003","journal-title":"Rev Venez Oncol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(01)90039-3"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2390"},{"key":"e_1_2_6_28_2","first-page":"796","article-title":"Results of the randomised international trial FAB LMB\u201096 for the \u201cintermediate risk\u201d childhood and adolescent B\u2010cell lymphoma: Reduce therapy is efficacious","volume":"22","author":"Patte C","year":"2003","journal-title":"Proc Am Soc Oncol"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90228-E"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20116","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T18:19:23Z","timestamp":1696702763000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["10.1002\/pbc.20116"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20116","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,28]]}}}